Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

NCT01605825 ·Status: COMPLETED ·Phase: PHASE2

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia

NCT01898884 ·Status: COMPLETED ·Phase: PHASE1

Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia

NCT02363075 ·Status: UNKNOWN ·Phase: PHASE3

Phase 3 Study of Dexpramipexole in ALS

NCT01281189 ·Status: COMPLETED ·Phase: PHASE3

Dexpramipexole SAD/MAD Study

NCT01449578 ·Status: COMPLETED ·Phase: PHASE1

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

NCT05178810 ·Status: COMPLETED ·Phase: PHASE3

Use of Dalfampridine in Primary Lateral Sclerosis

NCT02868567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

NCT03781479 ·Status: COMPLETED ·Phase: PHASE2

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720 ·Status: APPROVED_FOR_MARKETING

Dexpramipexole Renal PK Study

NCT01424176 ·Status: COMPLETED ·Phase: PHASE1

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950 ·Status: APPROVED_FOR_MARKETING

Study of NMDA Antagonists and Neuropathic Pain

NCT01602185 ·Status: COMPLETED ·Phase: PHASE2

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

NCT00004832 ·Status: COMPLETED ·Phase: NA

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT00041717 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518 ·Status: COMPLETED ·Phase: PHASE2

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

NCT00374075 ·Status: COMPLETED ·Phase: PHASE1

Memantine for Enhanced Stroke Recovery

NCT02144584 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke

NCT01016119 ·Status: COMPLETED ·Phase: PHASE3

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

NCT03819660 ·Status: TERMINATED ·Phase: PHASE2

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125 ·Status: RECRUITING ·Phase: PHASE3

A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

NCT03917225 ·Status: COMPLETED ·Phase: PHASE2

Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo

NCT01450865 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375 ·Status: TERMINATED ·Phase: PHASE2

Treatment Use of 3,4-Diaminopyridine

NCT01765140 ·Status: NO_LONGER_AVAILABLE